Clinical Trial Update: An Observational Study of Adjuvant (Post-surgery) Therapy With Nivolumab for Resected (Completely Removed) Melanoma in Australia

View source ↗

Summary

An observational study in Australia is evaluating adjuvant nivolumab after surgical resection of melanoma; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• nivolumab (Opdivo) (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Melanoma | Status: COMPLETED